EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole

Clin Microbiol Infect. 2012 Jul;18(7):E248-50. doi: 10.1111/j.1469-0691.2012.03890.x. Epub 2012 Apr 30.

Abstract

The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B, itraconazole and posaconazole for Aspergillus species. This Technical Note is based on the EUCAST amphotericin B, itraconazole and posaconazole rationale documents (available on the EUCAST website: http://www.eucast.org/antifungal_susceptibility_testing_afst/rationale_documents_for_antifungals/). The amphotericin B and itraconazole breakpoints are based on epidemiological cut-off values and clinical experience. The posaconazole breakpoints are also based on pharmacokinetic and pharmacodynamic data. Breakpoints will be reviewed regularly or when new data emerge.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology*
  • Antifungal Agents / pharmacology*
  • Aspergillus / drug effects*
  • Europe
  • Humans
  • Itraconazole / pharmacology*
  • Microbial Sensitivity Tests / methods
  • Microbial Sensitivity Tests / standards
  • Triazoles / pharmacology*

Substances

  • Antifungal Agents
  • Triazoles
  • Itraconazole
  • posaconazole
  • Amphotericin B